XML 56 R15.htm IDEA: XBRL DOCUMENT
v3.25.4

Net Loss per Share | 12 Months Ended
--- | ---
Dec. 31, 2025
Earnings Per Share [Abstract] |
Net Loss per Share | Net Loss per Share The following table sets forth the computation of basic and diluted net loss per share:
| Year Ended December 31,
| 2025 |  | 2024 |  | 2023
Net loss | $ | (1,079,586) |  |  | $ | (221,315) |  |  | $ | (614,928) |
Basic and diluted weighted average number of shares of common stock outstanding | 747,702,265 |  |  | 718,541,896 |  |  | 619,646,180 |
Basic net loss per share | $ | (1.44) |  |  | $ | (0.31) |  |  | $ | (0.99) |
Diluted net loss per share | $ | (1.44) |  |  | $ | (0.31) |  |  | $ | (0.99) |
Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the diluted net loss by the weighted-average number of common shares outstanding for the period, including potentially dilutive common shares. Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share for all periods, as the inclusion of all potential common share equivalents outstanding would have been antidilutive. Because the 2023 Rights Offering (see Note 13) exercise price of $1.05 per share was less than the closing price of $1.82 per share on March 1, 2023, the expiration, the Company has retroactively adjusted earnings per share and the weighted average number of shares outstanding for the bonus element for the year ended December 31, 2023. The following potentially dilutive securities were excluded from the computation of the diluted net loss per share of common stock for the periods presented because their effect would have been anti-dilutive:
|  | Year Ended December 31,
|  | 2025 |  | 2024 |  | 2023
Options to purchase common stock |  | 115,614,728 |  | 68,920,334 |  | 54,209,289
Warrants |  | — |  | 4,629,988 |  | 5,015,642
Shares expected to be purchased under employee stock purchase plan |  | 65,905 |  | 86,550 |  | 155,163
Total |  | 115,680,633 |  | 73,636,872 |  | 59,380,094
Stock options that are outstanding and contain improbable vesting criteria are excluded from the presentation of common stock equivalents outstanding in the table above.

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration